An alpha-thalassemia genetic test looks for deletions and other disease-causing changes involving the HBA1 and HBA2 genes, which make alpha-globin chains used in hemoglobin. Most people have four functional alpha-globin genes—two on each chromosome 16. The number and arrangement of affected genes determine whether a result represents a silent carrier state, alpha-thalassemia trait, hemoglobin H disease, or the severe fetal condition known as alpha-thalassemia major or hemoglobin Bart hydrops fetalis. Genetic testing is especially valuable because a routine blood count and hemoglobin electrophoresis can miss silent carriers and cannot reliably show whether two missing genes are on the same chromosome or opposite chromosomes. That distinction, called cis versus trans configuration, can change reproductive risk dramatically. Testing usually begins with common deletion analysis and may expand to sequencing and copy-number analysis. Results should be interpreted with red-cell indices, iron studies, hemoglobin analysis, ancestry, family history, and the reproductive partner’s result.
- Four alpha-globin genes are normally present, so results are interpreted by how many genes are deleted or inactivated and how they are arranged.
- A one-gene loss usually means silent carrier status, often with normal hemoglobin and only subtle or no red-cell changes.
- A two-gene cis deletion, written –/αα, creates important pregnancy risk because two cis carriers can conceive a fetus with no functional alpha-globin genes.
- A two-gene trans result, written -α/-α, causes alpha-thalassemia trait but usually does not create alpha-thalassemia major risk with another trans carrier.
- Normal hemoglobin electrophoresis does not exclude alpha-thalassemia trait, so DNA testing is often needed when microcytosis persists without iron deficiency.
- Partner testing should follow a clinically significant carrier result, preferably before pregnancy or as early in pregnancy as possible.
Table of Contents
- How the four-gene alpha-globin system works
- Reasons to order HBA1 and HBA2 testing
- Deletion testing, sequencing, and other methods
- Silent carrier and trait result patterns
- Hemoglobin H disease and alpha-thalassemia major
- Partner combinations and pregnancy risk
- How DNA results fit with blood tests
- What to do after the report
How the four-gene alpha-globin system works
Alpha-globin is produced from two closely related genes, HBA1 and HBA2, positioned next to each other on each copy of chromosome 16. A typical chromosome carries one HBA2 gene and one HBA1 gene, represented as αα. With two chromosome 16 copies, most people have the arrangement αα/αα, for a total of four functional alpha-globin genes.
Alpha-thalassemia develops when one or more of those genes are deleted or cannot function. The shorthand is compact but clinically important:
- -α/αα: one affected gene; silent carrier
- –/αα: two affected genes on the same chromosome; cis alpha-thalassemia trait
- -α/-α: one affected gene on each chromosome; trans alpha-thalassemia trait
- –/-α: three affected genes; hemoglobin H disease
- –/–: four affected genes; alpha-thalassemia major, historically called hemoglobin Bart hydrops fetalis
A dash may represent a deletion, but some nondeletional variants also reduce or eliminate alpha-globin production. Reports may use symbols such as αᵀ or name a specific variant, including hemoglobin Constant Spring. Nondeletional changes can produce more severe disease than a simple deletion because an unstable or abnormal globin product may be made.
The arrangement matters as much as the count. Two people can both have mild microcytosis and two inactive genes, yet one may have –/αα and the other -α/-α. Their own blood findings can look similar, but their reproductive risks differ. That is one reason molecular testing adds information that a complete blood count cannot provide.
HBA1 and HBA2 are highly similar, which makes analysis technically challenging. The laboratory must use methods designed for the alpha-globin cluster and its upstream regulatory region. A generic sequencing panel may not resolve the locus fully, so the report’s methodology and limitations deserve close review.
Reasons to order HBA1 and HBA2 testing
Testing is commonly ordered after unexplained microcytosis—small red blood cells—appears on a complete blood count. Alpha-thalassemia trait often produces a low mean corpuscular volume, or MCV, and low mean corpuscular hemoglobin, or MCH, with a normal or mildly reduced hemoglobin concentration. The red blood cell count may be relatively high compared with iron deficiency.
Genetic testing may be appropriate when:
- MCV or MCH remains low after iron deficiency has been excluded
- A person has alpha-thalassemia trait suggested by blood indices but normal or nondiagnostic hemoglobin electrophoresis
- Newborn screening identifies hemoglobin Bart or hemoglobin H
- A relative has a known HBA1 or HBA2 deletion or pathogenic variant
- A reproductive partner has a cis two-gene deletion, hemoglobin H disease, or another clinically important alpha-globin result
- Prenatal ultrasound shows fetal hydrops, severe anemia, placental enlargement, or another pattern raising concern for alpha-thalassemia major
- A couple is undergoing preconception or prenatal carrier screening
- A patient has chronic hemolytic anemia, splenomegaly, or findings suggesting hemoglobin H disease
Population background can influence which deletions are most likely, but testing should not be withheld based on self-identified ancestry. Alpha-thalassemia variants occur in people with Southeast Asian, southern Chinese, Middle Eastern, Mediterranean, African, South Asian, Pacific Islander, and many mixed ancestries. Population-neutral carrier screening can identify people who would be missed by ancestry-based assumptions.
Iron deficiency and alpha-thalassemia can coexist. A low ferritin does not prove that iron deficiency explains all microcytosis, and correcting iron deficiency may reveal persistent small red cells from thalassemia trait. Conversely, a presumptive alpha-thalassemia label should not be used to ignore true iron deficiency, bleeding, or another cause of anemia.
Testing in pregnancy is time-sensitive when one partner has a cis deletion. The other partner should be tested promptly because a high-risk combination may lead to diagnostic testing of the fetus. Screening and diagnostic testing are different: parental carrier testing estimates risk, while chorionic villus sampling or amniocentesis can determine the fetal genotype.
Deletion testing, sequencing, and other methods
Because most alpha-thalassemia is caused by deletions, the testing sequence differs from many other inherited disorders. Laboratories often begin with targeted analysis for common deletions, then broaden the assay when results do not explain the blood findings or family history.
Common deletion analysis
Targeted assays may detect frequent single-gene deletions such as -α3.7 and -α4.2, along with two-gene deletions such as –SEA, –FIL, –MED, –THAI, and others chosen for the population served. A targeted panel is efficient, but a negative result only excludes the variants included.
Deletion and duplication analysis
Methods such as multiplex ligation-dependent probe amplification, or MLPA, can detect uncommon deletions and duplications across HBA1, HBA2, and nearby regulatory elements. This is important when targeted deletion testing is negative but alpha-thalassemia remains likely. Copy-number testing may also identify alpha-globin gene triplication or quadruplication, which can modify beta-thalassemia severity.
Sequence analysis
Sequencing identifies nondeletional variants, including changes that alter coding sequence, splicing, initiation, termination, or gene regulation. Hemoglobin Constant Spring is a familiar example. Because HBA1 and HBA2 have near-identical sequences, the assay must reliably assign a variant to the correct gene.
Phase and parental studies
“Phase” describes whether two variants are on the same chromosome or opposite chromosomes. Some reports infer cis or trans arrangement from the deletion itself, while complex cases may require testing parents or another relative. Phase is central to reproductive counseling.
| Method | What it can find | What it may miss |
|---|---|---|
| Targeted deletion panel | Selected common one- and two-gene deletions | Rare deletions and nondeletional variants |
| MLPA or comparable copy-number assay | Uncommon deletions, duplications, and regulatory-region losses | Many small sequence variants |
| HBA1/HBA2 sequencing | Point variants and small insertions or deletions | Some large rearrangements without added copy-number analysis |
| Gap-PCR | A specifically targeted known deletion | Variants outside the assay targets |
| Long-read or specialized haplotype testing | Complex structures and phase in selected laboratories | May not be routinely available |
A blood or saliva sample is usually sufficient. Fasting is unnecessary, and iron therapy does not change DNA. Transfusion can distort hemoglobin analysis and some blood indices, but it does not usually change germline DNA from white blood cells. Recent bone-marrow transplantation can complicate blood-based genetic testing because the white cells may be donor-derived; another tissue may be needed.
Turnaround time ranges from several days for a known familial deletion to several weeks for comprehensive analysis. Before testing, confirm whether the laboratory reports the alpha-globin haplotype, whether it distinguishes HBA1 from HBA2 for sequence variants, and whether its deletion assay covers the MCS-R2 regulatory region. These details become especially important when one partner already carries a cis deletion. A report that simply says “alpha-thalassemia positive” may be insufficient for reproductive counseling.
For prenatal diagnosis, the molecular laboratory often asks for both parental reports and samples before chorionic villus sampling or amniocentesis. A maternal blood sample may be required to check for maternal-cell contamination. If a familial deletion has not been characterized fully, testing the fetus first can create delays or an ambiguous result. Early coordination among the ordering clinician, genetics team, procedure center, and laboratory helps ensure the correct assay is ready when the sample arrives.
Silent carrier and trait result patterns
A carrier result is not simply “positive” or “negative.” The report should identify the number of affected genes, the specific deletion or variant, and the chromosomal arrangement when known.
One affected alpha-globin gene
A result such as -α/αα indicates a silent carrier. Hemoglobin is usually normal, and MCV may be normal or only slightly low. Hemoglobin electrophoresis after infancy is often normal. The person generally does not need treatment, but the result can matter when a partner carries a two-gene deletion or hemoglobin H–causing arrangement.
A nondeletional single-gene variant may not behave exactly like a common deletion. HBA2 contributes more alpha-globin than HBA1, so an HBA2 variant can have a larger hematologic effect. The laboratory’s variant-specific interpretation is therefore more informative than gene counting alone.
Two affected genes in trans
The -α/-α pattern means one alpha-globin gene is inactive on each chromosome. This causes alpha-thalassemia trait, typically with lifelong microcytosis and mild or no anemia. It is common in some African populations. Two trans carriers generally cannot produce a –/– fetus using only their -α chromosomes because each parent still passes a chromosome containing one functional alpha gene.
Two affected genes in cis
The –/αα pattern also causes alpha-thalassemia trait, but both genes are absent from one chromosome. This arrangement is more common in several Southeast Asian populations and occurs in other groups as well. It has greater reproductive significance because two cis carriers can each pass a — chromosome, creating a 25% chance of –/– in every pregnancy.
Do not use the word “minor” to minimize reproductive relevance. The carrier’s own health effects may be mild, yet the phase can determine whether a pregnancy is at risk for severe fetal anemia. A result should be documented precisely rather than recorded only as “alpha-thal trait.”
Alpha-thalassemia trait is often mistaken for iron deficiency, leading to years of unnecessary iron supplements. Iron should be taken when deficiency is documented, not merely because MCV is low. Excess iron can be harmful, particularly in people with hemoglobin H disease who may accumulate iron even without regular transfusions.
Hemoglobin H disease and alpha-thalassemia major
Three affected alpha-globin genes usually produce hemoglobin H disease, written –/-α for a deletional form or a comparable deletion/nondeletion combination. With only one functioning alpha-globin gene, excess beta chains form hemoglobin H in adults. Red cells become fragile, causing chronic hemolytic anemia of variable severity.
People with deletional hemoglobin H disease may have mild to moderate anemia, jaundice during illness, an enlarged spleen, gallstones, and episodes of worsened hemolysis. Nondeletional hemoglobin H disease—such as a two-gene deletion paired with hemoglobin Constant Spring—often causes more severe anemia, greater transfusion needs, splenomegaly, and iron overload.
Four inactive genes, –/–, cause alpha-thalassemia major. During fetal life, the lack of alpha chains leads to hemoglobin Bart, made from four gamma chains. Hemoglobin Bart binds oxygen too tightly and cannot deliver it effectively to tissues. Severe fetal anemia can cause hydrops, heart failure, placental enlargement, growth problems, and maternal complications including preeclampsia, hemorrhage, and mirror syndrome.
Alpha-thalassemia major was once considered uniformly fatal before or shortly after birth. Intrauterine transfusion and intensive postnatal treatment have allowed survival in selected cases, but the condition requires highly specialized maternal-fetal medicine, hematology, neonatology, transfusion, and long-term multidisciplinary care. Early diagnosis can change management and maternal safety.
A positive fetal result should be interpreted urgently and compassionately. Options may include expectant management, intrauterine transfusion, pregnancy termination where legal and desired, or palliative planning. Counseling should cover maternal risk, uncertainty in neurologic and long-term outcomes, the burden of lifelong transfusions, and the family’s values.
Partner combinations and pregnancy risk
The partner’s exact genotype determines the chance of hemoglobin H disease or alpha-thalassemia major. A general “carrier” label is not enough.
| Parent 1 | Parent 2 | Important possible outcome |
|---|---|---|
| –/αα | –/αα | 25% –/– alpha-thalassemia major |
| –/αα | -α/αα | 25% –/-α hemoglobin H disease |
| –/αα | -α/-α | 50% chance of hemoglobin H disease |
| -α/-α | -α/-α | Children may have trait or silent carrier states, but not –/– from these alleles alone |
| –/αα | αᵀα/αα | Risk depends on the nondeletional variant and its chromosome; hemoglobin H disease may occur |
These probabilities assume the stated genotypes and restart with each pregnancy. Complex variants can change the calculation, so a genetic counselor should use the actual laboratory reports.
When one partner has a two-gene cis deletion, the other partner should have testing capable of detecting both deletions and nondeletional variants. A limited test that checks only a few common deletions may leave substantial residual risk. The same concern applies to expanded carrier screening: panel inclusion does not guarantee complete coverage of HBA1, HBA2, and the alpha-globin regulatory region.
Reproductive options include natural conception with or without prenatal diagnosis, IVF with preimplantation genetic testing for a monogenic disorder, donor gametes, donor embryos, and adoption. Some families use testing to prepare rather than to avoid an affected pregnancy. Counseling should be nondirective and should distinguish a carrier state from hemoglobin H disease and alpha-thalassemia major.
How DNA results fit with blood tests
A complete blood count, reticulocyte count, ferritin, iron studies, peripheral smear, and hemoglobin analysis provide information that DNA alone cannot. The findings also help identify coexisting conditions.
Typical alpha-thalassemia trait findings include low MCV and MCH, a normal or mildly low hemoglobin level, and a red blood cell count that is normal to high. HbA2 is usually normal or low-normal, unlike beta-thalassemia trait, in which HbA2 is often elevated. Hemoglobin electrophoresis can be normal in both silent carrier status and alpha-thalassemia trait.
Newborn screening may detect hemoglobin Bart because gamma-chain tetramers form when alpha chains are limited. The percentage can suggest severity, but cutoffs and reporting vary by program. A small amount may indicate one- or two-gene loss, while a larger amount raises concern for hemoglobin H disease. Confirmatory molecular testing is needed.
Microcytosis also occurs with iron deficiency, beta-thalassemia, anemia of inflammation, lead exposure, and some rare disorders of heme or iron metabolism. Coinheritance can alter the expected pattern. Alpha-thalassemia may reduce the severity of some beta-thalassemia states, while alpha-globin gene triplication can worsen beta-thalassemia.
A negative genetic report needs to be read against the assay coverage. If only common deletions were tested, uncommon deletions, regulatory variants, and nondeletional HBA1 or HBA2 variants remain possible. A broader deletion and duplication test or specialized sequencing may be appropriate when the phenotype remains convincing.
What to do after the report
For a silent carrier or uncomplicated trait result, medical treatment is usually unnecessary. Keep the report, avoid automatic iron supplementation without evidence of deficiency, and make sure the reproductive partner is tested when relevant. The diagnosis should be recorded clearly so future clinicians do not repeatedly investigate the same lifelong microcytosis.
After hemoglobin H disease is diagnosed, follow-up may include:
- Establish care with a hematologist experienced in thalassemia.
- Obtain baseline hemoglobin, reticulocyte count, bilirubin, liver tests, and iron status.
- Develop a plan for fever, infection, pregnancy, surgery, or sudden worsening of anemia.
- Avoid oxidant medicines only when specifically advised; do not use broad medication restrictions without evidence.
- Monitor iron loading, including in people who are not regularly transfused.
- Discuss folate, transfusion thresholds, gallstones, spleen issues, and pregnancy care individually.
- Test relatives who may have reproductive or health implications.
After a high-risk couple result, referral should occur promptly to genetics and maternal-fetal medicine. Chorionic villus sampling can often provide an earlier fetal diagnosis than amniocentesis, but timing, procedure risk, laboratory readiness, and local availability must be reviewed. The familial variants should be confirmed before an invasive sample is collected whenever possible.
A variant of uncertain significance should not be used alone to declare a pregnancy affected. Ask whether phase studies, parental testing, blood indices, hemoglobin analysis, or reclassification review could clarify it. Clinical decisions should rest on the full evidence, not the presence of unfamiliar genetic wording.
Families should also request an explanation of residual risk after a negative partner test. Residual risk is lowest when the assay includes common and uncommon deletions, relevant regulatory regions, and HBA1/HBA2 sequencing. It is higher after a small ancestry-specific panel. The laboratory may not be able to reduce risk to zero, but it should state what variant types remain outside its detection range.
References
- Alpha-Thalassemia 2024 (Review)
- Guidelines for the Management of α-Thalassaemia 2023 (Guideline)
- Αlpha-thalassemia: A practical overview 2024 (Review)
- Disease burden, management strategies, and unmet needs in α-thalassemia 2024 (Review)
- Screening for autosomal recessive and X-linked conditions during pregnancy and preconception: a practice resource of the American College of Medical Genetics and Genomics (ACMG) 2021 (Practice Resource)
- Laboratory testing for preconception/prenatal carrier screening: a technical standard of the American College of Medical Genetics and Genomics (ACMG) 2024 (Technical Standard)
Disclaimer
This information is educational and does not replace interpretation by a hematologist, medical geneticist, obstetric clinician, or genetic counselor. The reproductive meaning of an HBA1 or HBA2 result depends on the exact variant, cis or trans arrangement, test coverage, and the partner’s genotype. Urgent specialist care is needed for suspected fetal hydrops, severe anemia, jaundice with illness, or rapid clinical deterioration.
